ACHC · Acadia Healthcare Company, Inc. · Debt

On March 10, 2025, Acadia Healthcare Company, Inc. (the “Company”), entered into an Indenture, dated as of March 10, 2025 (the “Indenture”), by and among the Company, the guarantors party thereto (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), in connection with the sale and issuance of $550 million aggregate principal amount of 7.375% Senior Notes due 2033 (the “Notes”) to J.P. Morgan Securities LLC and certain other initial purchasers in a private offering (the “Offering”) exempt from registration requirements under the Securities Act of 1933, as amended (the “Securities Act”) to qualified institutional buyers in the United States, as defined in Rule 144A under the Securities Act, and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.

Issuer evidence: On March 10, 2025, Acadia Healthcare Company, Inc. (the “Company”), entered into an Indenture, dated as of March 10, 2025 (the “Indenture”), by and among the Company, the guarantors party thereto (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), in connection with the sale and issuance of $550 million aggregate principal amount of 7.375% Senior Notes due 2033 (the “Notes”) to J.P. Morgan Securities LLC and certain other initial purchasers in a private offering (the “Offering”) exempt from registration requirements under the Securities Act of 1933, as amended (the “Securities Act”) to qualified institutional buyers in the United States, as defined in Rule 144A under the Securities Act, and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.

Supporting evidence: The Notes will mature on March 15, 2033 and bear interest at a rate of 7.375% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2025. The Notes are the Company’s senior unsecured obligations and are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by the Guarantors.

Supporting evidence: On March 10, 2025, Acadia Healthcare Company, Inc. (the “Company”), entered into an Indenture, dated as of March 10, 2025 (the “Indenture”), by and among the Company, the guarantors party thereto (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), in connection with the sale and issuance of $550 million aggregate principal amount of 7.375% Senior Notes due 2033 (the “Notes”) to J.P. Morgan Securities LLC and certain other initial purchasers in a private offering (the “Offering”) exempt from registration requirements under the Securities Act of 1933, as amended (the “Securities Act”) to qualified institutional buyers in the United States, as defined in Rule 144A under the Securities Act, and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.

Supporting evidence: On March 10, 2025, Acadia Healthcare Company, Inc. (the “Company”), entered into an Indenture, dated as of March 10, 2025 (the “Indenture”), by and among the Company, the guarantors party thereto (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), in connection with the sale and issuance of $550 million aggregate principal amount of 7.375% Senior Notes due 2033 (the “Notes”) to J.P. Morgan Securities LLC and certain other initial purchasers in a private offering (the “Offering”) exempt from registration requirements under the Securities Act of 1933, as amended (the “Securities Act”) to qualified institutional buyers in the United States, as defined in Rule 144A under the Securities Act, and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.